Data / Drug companies / Dr. Reddy's Laboratories Inc.
Dr. Reddy's Laboratories Inc.: 416 products in the FDA NDC directory, labeler code 43598
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Dr. Reddy's Laboratories Inc. (labeler code 43598) lists 416 products in the FDA National Drug Code Directory, covering 152 finished drugs by generic name. By type: 327 prescription drugs, 66 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 5, 2026.
The request: Watch Dr. Reddy's Laboratories Inc. (FDA labeler code 43598): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 43598
- Products in commercial distribution
- 416
- Packages
- 874
- Finished drugs by generic name
- 152
- Prescription products
- 327
- Over the counter products
- 66
- Controlled substance products
- Schedule II 2, Schedule III 5, Schedule IV 6, Schedule V 9
- Flagged as original packager
- 358 of 358 products that carry the flag
- Started marketing in the last 12 months
- 30
- Products with a marketing end date set
- 11
- Earliest marketing start
- May 4, 2011
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 379 | 91.1% |
| Drugs for further processing | 23 | 5.5% |
| New drug applications (NDA) | 8 | 1.9% |
| Authorized generics (NDA) | 6 | 1.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 327 | 78.6% |
| Over the counter drugs | 66 | 15.9% |
| Drugs for further processing | 21 | 5% |
| Bulk ingredients | 2 | 0.5% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 65 | 15.6% |
| Tablet | 63 | 15.1% |
| Capsule | 44 | 10.6% |
| Injection, solution | 34 | 8.2% |
| Injection | 30 | 7.2% |
| Tablet, extended release | 20 | 4.8% |
| Injection, powder, lyophilized, for solution | 19 | 4.6% |
| Lozenge | 18 | 4.3% |
| Capsule, delayed release | 15 | 3.6% |
| Tablet, film coated, extended release | 11 | 2.6% |
| Tablet, coated | 10 | 2.4% |
| Solution | 8 | 1.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Phytonadione | 43598-032 | Injection, emulsion | Generic drugs (ANDA) | October 5, 2026 |
| Docosanol | 43598-946 | Cream | Generic drugs (ANDA) | October 1, 2026 |
| Docosanol | 43598-044 | Cream | Generic drugs (ANDA) | September 23, 2026 |
| Pomalidomide | 43598-520 | Capsule | Generic drugs (ANDA) | August 31, 2026 |
| Pomalidomide | 43598-519 | Capsule | Generic drugs (ANDA) | August 31, 2026 |
| Pomalidomide | 43598-518 | Capsule | Generic drugs (ANDA) | August 31, 2026 |
| Pomalidomide | 43598-517 | Capsule | Generic drugs (ANDA) | August 31, 2026 |
| Permethrin | 43598-481 | Cream | Generic drugs (ANDA) | August 26, 2026 |
| Prednisone delayed release | 43598-888 | Tablet, delayed release | Generic drugs (ANDA) | August 12, 2026 |
| Sugammadex | 43598-925 | Injection, solution | Generic drugs (ANDA) | July 28, 2026 |
| Sugammadex | 43598-924 | Injection, solution | Generic drugs (ANDA) | July 28, 2026 |
| Nintedanib | 43598-148 | Capsule | Generic drugs (ANDA) | April 2, 2026 |
| Nintedanib | 43598-147 | Capsule | Generic drugs (ANDA) | April 2, 2026 |
| Eltrombopag | 43598-732 | Tablet, film coated | Generic drugs (ANDA) | March 17, 2026 |
| Eltrombopag | 43598-731 | Tablet, film coated | Generic drugs (ANDA) | March 17, 2026 |
| Eltrombopag | 43598-730 | Tablet, film coated | Generic drugs (ANDA) | March 17, 2026 |
| Eltrombopag | 43598-151 | Tablet, film coated | Generic drugs (ANDA) | March 17, 2026 |
| Pralatrexate | 43598-343 | Injection | Generic drugs (ANDA) | March 4, 2026 |
| Pralatrexate | 43598-342 | Injection | Generic drugs (ANDA) | March 4, 2026 |
| Fosaprepitant | 43598-671 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | February 12, 2026 |
| Topiramate | 43598-942 | Capsule, extended release | Generic drugs (ANDA) | February 1, 2026 |
| Topiramate | 43598-941 | Capsule, extended release | Generic drugs (ANDA) | February 1, 2026 |
| Topiramate | 43598-940 | Capsule, extended release | Generic drugs (ANDA) | February 1, 2026 |
| Topiramate | 43598-939 | Capsule, extended release | Generic drugs (ANDA) | February 1, 2026 |
| Eribulin Mesylate | 43598-125 | Injection | Generic drugs (ANDA) | January 22, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.